STOCK TITAN
  1. Home
  2. QSAM

QSAM Biosciences (QSAM) Stock Price, News & Analysis

QSAM OTC
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
34 253 sessions, May 2, 2023 to May 2, 2024
Largest daily move
+200327.5% close of December 11, 2023
1-year change
-99.9% closing prices, May 2, 2023 to May 2, 2024
1-month change
-99.9% closing prices, April 2, 2024 to May 2, 2024

Company Description

QSAM declined 99.9% in the 12 months to May 2, 2024. The last closing price was $8.30.

This page collects what Stock Titan holds for QSAM, including price data and latest news.

Stock Performance

Chart
$8.30
No recent trading
Last close: May 2, 2024
-99.9%
1 year to May 2, 2024
-
Market Cap
-
Shares outstanding

QSAM Biosciences (QSAM) closed at $8.30 on May 2, 2024. In the 12 months to May 2, 2024, the price lost 99.9%.

See what a $1,000 investment in QSAM would be worth today

Average down calculator for QSAM

QSAM Metrics & Rankings

May 2024
-99.9%
—
2024
-99.9%
—

Price returns through May 2, 2024. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
0.00%

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER

stock split acquisition
+31.57%

QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals

acquisition
+34.77%

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

acquisition
+0.59%

QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data

clinical trial
+1.06%

QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®

-1.96%

QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center

+2.00%

QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®

+22.61%

QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®

+8.97%

QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

clinical trial
+2.59%

QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023

clinical trial

QSAM Biosciences has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 1 with negative movement. Key topics include stock split, acquisition, clinical trial. View all QSAM news →

SEC Filings

No SEC filings available for QSAM.

Frequently Asked Questions

QSAM Biosciences (QSAM) has no recent trading. Its last close was $8.30 on May 2, 2024.